Ticker

Onconetix, Inc. (NASDAQ: ONCO - Get Free Report) was the recipient of a significant drop in short interest during the month of January. As of January 30th, there was short interest totaling 107,197 shares, a drop of 13.9% from the January 15th total of 124,512 shares. Based on an average daily trading volume, of 212,934 shares,

Onconetix, Inc. (ONCO) M&A Call Transcript

A leading AI and humanoid robotics company has commercially available models designed, built and manufactured in the United States of America  CINCINNATI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) (“Onconetix” or the “Company”), (formerly Blue Water Biotech Inc), and Realbotix LLC. (“Realbotix”), a wholly-owned subsidiary of Realbotix Corp. (TSX-V: XBOT) (“Realbotix Parent “), today announced…

LAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Parent Company”), a leader in AI-powered humanoid robots, announces it has entered into a definitive agreement with Onconetix, Inc (NASDAQ: ONCO) (“ONCO”), pursuant to which ONCO will acquire 100% of Realbotix, LLC (“RealLLC” or the “Subsidiary”), a wholly owned subsidiary of Realbotix in an all-stock…

Onconetix (NASDAQ: ONCO - Get Free Report) and AstraZeneca (NASDAQ: AZN - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability. Insider and Institutional Ownership 23.9% of Onconetix shares are owned